Steady growth and active M&As should continue
12/05/22 -"Bastide’s Q3 revenue continued to be affected by last year’s pandemic-led unfavourable comparable base but the anomalies should not persist for long. The group has maintained its FY guidance ..."
Pages
50
Language
English
Published on
12/05/22
You may also be interested by these reports :
29/07/26
bioMerieux’s H1 profitability largely met expectations. Q2 sales growth was driven by increases across both segments, supported by its GO28 growth ...
28/07/26
Philips’ Q2 sales surpassed expectations, with profitability excluding one-offs meeting forecasts. The 2026 guidance was reaffirmed. However, ...
24/07/26
Sartorius reported mixed Q2 26 numbers, with revenue below consensus (-2.3%) but underlying EBITDA slightly ahead (+0.5%). Equipment inflected as ...
23/07/26
Sartorius Stedim Biotech reported mixed Q2 26 numbers, with revenue below consensus (-2.8%) but underlying EBITDA ahead (+1.1%). The miss is largely ...